Inventor · disambiguated record
Francis Xavier Tavares
Also filed as: TAVARES FRANCIS X · TAVARES FRANCIS XAVIER
47 granted patents·27 pending applications·798 citations·filing 2000–2025
99Inventor score
Files withG1 THERAPEUTICS INC49SMITHKLINE BEECHAM CORP5NOVATARG INC4RESILIO THERAPEUTICS LLC4SYMBERIX INC3
Top patents by PatentIndex Score
74 records- 0199US10189850B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·17 cites·1 claims
- 0299US10189849B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·18 cites·1 claims
- 0399US10189851B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jan 29, 2019·19 cites·1 claims
- 0499US9499564B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2015·Granted Nov 22, 2016·34 cites·2 claims
- 0599US9481691B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2015·Granted Nov 1, 2016·31 cites·2 claims
- 0699US9102682B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Aug 11, 2015·42 cites·16 claims
- 0799US8829012B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Sep 9, 2014·47 cites·47 claims
- 0899US8822683B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Sep 2, 2014·55 cites·37 claims
- 0999US8691830B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2013·Granted Apr 8, 2014·53 cites·42 claims
- 1099US8598197B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2013·Granted Dec 3, 2013·65 cites·58 claims
- 1199US8598186B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2013·Granted Dec 3, 2013·81 cites·24 claims
- 1298US11040042B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2020·Granted Jun 22, 2021·5 cites·2 claims
- 1398US10927120B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2020·Granted Feb 23, 2021·5 cites·3 claims
- 1498US10085992B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2016·Granted Oct 2, 2018·16 cites·9 claims
- 1598US10076523B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2016·Granted Sep 18, 2018·15 cites·15 claims
- 1698US9957276B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2016·Granted May 1, 2018·14 cites·57 claims
- 1798US9931345B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2016·Granted Apr 3, 2018·14 cites·20 claims
- 1898US9527857B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2014·Granted Dec 27, 2016·31 cites·74 claims
- 1998US9487530B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2014·Granted Nov 8, 2016·36 cites·50 claims
- 2098US9464092B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2014·Granted Oct 11, 2016·29 cites·54 claims
- 2197US11717523B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2021·Granted Aug 8, 2023·3 cites·21 claims
- 2297US11654148B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2021·Granted May 23, 2023·4 cites·16 claims
- 2397US10696682B2CDK inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Jun 30, 2020·6 cites·12 claims
- 2497US10434104B2HSPC-sparing treatments for Rb-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2018·Granted Oct 8, 2019·7 cites·10 claims
- 2597US9260442B2Lactam kinase inhibitorsG1 THERAPEUTICS INC·Filed 2014·Granted Feb 16, 2016·42 cites·14 claims
- 2696US10925878B2HSPC-sparing treatments for RB-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2018·Granted Feb 23, 2021·5 cites·85 claims
- 2796US10709711B2Highly active anti-neoplastic and anti-proliferative agentsG1 THERAPEUTICS INC·Filed 2018·Granted Jul 14, 2020·6 cites·8 claims
- 2896US10660896B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2018·Granted May 26, 2020·5 cites·21 claims
- 2995US10966984B2Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2018·Granted Apr 6, 2021·5 cites·30 claims
- 3095US9745316B2Lactam kinase inhibitorsG1 THERAPEUTICS INC·Filed 2015·Granted Aug 29, 2017·14 cites·20 claims
- 3192US10865210B2Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-aminesG1 THERAPEUTICS INC·Filed 2018·Granted Dec 15, 2020·9 cites·37 claims
- 3292US9856268B2Lactam kinase inhibitorsG1 THERAPEUTICS INC·Filed 2016·Granted Jan 2, 2018·9 cites·20 claims
- 3391US11629150B2Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-aminesG1 THERAPEUTICS INC·Filed 2020·Granted Apr 18, 2023·3 cites·5 claims
- 3489US10464940B2Lactam kinase inhibitorsG1 THERAPEUTICS INC·Filed 2018·Granted Nov 5, 2019·5 cites·16 claims
- 3589US2023381189A1Transient protection of normal cells during chemotherapyG1 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3688US11834411B2Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapyNOVATARG INC·Filed 2022·Granted Dec 5, 2023·2 cites·5 claims
- 3788US10202392B2Synthesis of lactamsTAVARES FRANCIS XAVIER·Filed 2013·Granted Feb 12, 2019·6 cites·15 claims
- 3888US2023364098A1Hspc-sparing treatments for rb-positive abnormal cellular proliferationG1 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3987US11261157B2Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapyNOVATARG INC·Filed 2017·Granted Mar 1, 2022·4 cites·9 claims
- 4087US2024109906A1Cdk inhibitorsG1 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4183US12371404B2Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapyNOVATARG INC·Filed 2023·Granted Jul 29, 2025·0 cites·1 claims
- 4282US6649366B2Methods and compositions related to modulators of annexin and cartilage homeostasisSMITHKLINE BEECHAM CORP·Filed 2000·Granted Nov 18, 2003·21 cites·3 claims
- 4382US2023248733A1Highly active anti-neoplastic and anti-proliferative agentsG1 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4480US2025326719A1Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapyNOVATARG INC·Filed 2025·Application pending·0 cites
- 4578US2021395259A1Cdk inhibitorsG1 THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4675US7582630B2Pyradazine compounds as GSK-3 inhibitorsSMITHKLINE BEECHAM CORP·Filed 2003·Granted Sep 1, 2009·7 cites·8 claims
- 4774US2019167691A1Transient protection of hematopoietic stem and progenitor cells against ionizing radiationG1 THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4874US2021077498A1Transient protection of hematopoietic stem and progenitor cells against ionizing radiationG1 THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4973US12017994B2Compounds, compositions, and methods for selectively inhibiting β-glucuronidases and alleviating side effects associated with drug treatment induced diarrheaSYMBERIX INC·Filed 2018·Granted Jun 25, 2024·1 cites·12 claims
- 5072US2020345743A1Highly active anti-neoplastic and anti-proliferative agentsG1 THERAPEUTICS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 74 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Francis Xavier Tavares files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →